6533b853fe1ef96bd12ad73a
RESEARCH PRODUCT
Nonexposed Variant of Bisphosphonate-associated Osteonecrosis of the Jaw: A Case Series
Naom YaromNaom YaromAnna MusciottoMaddalena ManfrediRoberto BroccolettiGiuseppina CampisiStefano FedeleStephen PorterSuad AljohaniFrancesco D'aiutoOlga Di FedeTony S. LazaroviciPaolo G. ArduinoPaolo Vescovisubject
OsteochemonecrosisMaleTime FactorsAvascular necrosisMandibleAvascular necrosiEpidemiologyMaxillaProspective cohort studyMultiple myelomaAged 80 and overeducation.field_of_studyAlendronateBone Density Conservation AgentsDiphosphonatesOsteochemonecrosiOsteonecrosisGeneral MedicineBisphosphonatesMiddle AgedKidney NeoplasmsEuropeAvascular necrosisFemaleMultiple MyelomaAdultmedicine.medical_specialtyPopulationJawsBreast NeoplasmsSettore MED/28 - Malattie OdontostomatologicheJawbonesmedicineHumansBisphosphonateeducationAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryProstatic NeoplasmsAvascular necrosis; Bisphosphonates; Jawbones; Jaws; Mandible; Maxilla; Osteochemonecrosis; Osteonecrosismedicine.diseaseDermatologySurgeryJawMaxillaOsteoporosisJawbonebusinessOsteonecrosis of the jawJaw Diseasesdescription
Abstract Purpose To report a case series of patients with the nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw—a form of jaw osteonecrosis that does not manifest with necrotic bone exposure/mucosal fenestration. Methods Among 332 individuals referred to 5 clinical centers in Europe because of development of jawbone abnormalities after or during exposure to bisphosphonates, we identified a total of 96 patients who presented with the nonexposed variant of osteonecrosis. Relevant data were obtained via clinical notes; radiological investigations; patients' history, and referral letters. Results The most common clinical feature of nonexposed osteonecrosis was jaw bone pain (88/96; 91.6%); followed by sinus tract (51%), bone enlargement (36.4%); and gingival swelling (17.7%). No radiological abnormalities were identified in 29.1% (28/96) of patients. In 53.1% (51/96) of the patients; nonexposed osteonecrosis subsequently evolved into frank bone exposure within 4.6 months (mean; 95% confidence interval; 3.6-5.6). Conclusions Clinicians should be highly vigilant to identify individuals with nonexposed osteonecrosis, as the impact on epidemiological data and clinical trial design could be potentially significant. Although the present case series represents approximately 30% of all patients with bisphosphonates-associated osteonecrosis observed at the study centers, further population-based prospective studies are needed to obtain robust epidemiological figures.
year | journal | country | edition | language |
---|---|---|---|---|
2010-01-01 |